Cargando…

Receptors Involved in Mental Disorders and the Use of Clozapine, Chlorpromazine, Olanzapine, and Aripiprazole to Treat Mental Disorders

Mental illnesses are a global health challenge, and effective medicines are needed to treat these conditions. Psychotropic drugs are commonly prescribed to manage mental disorders, such as schizophrenia, but unfortunately, they can cause significant and undesirable side effects, such as myocarditis,...

Descripción completa

Detalles Bibliográficos
Autores principales: Mlambo, Ronald, Liu, Jia, Wang, Qian, Tan, Songwen, Chen, Chuanpin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10142280/
https://www.ncbi.nlm.nih.gov/pubmed/37111360
http://dx.doi.org/10.3390/ph16040603
_version_ 1785033575619362816
author Mlambo, Ronald
Liu, Jia
Wang, Qian
Tan, Songwen
Chen, Chuanpin
author_facet Mlambo, Ronald
Liu, Jia
Wang, Qian
Tan, Songwen
Chen, Chuanpin
author_sort Mlambo, Ronald
collection PubMed
description Mental illnesses are a global health challenge, and effective medicines are needed to treat these conditions. Psychotropic drugs are commonly prescribed to manage mental disorders, such as schizophrenia, but unfortunately, they can cause significant and undesirable side effects, such as myocarditis, erectile dysfunction, and obesity. Furthermore, some schizophrenic patients may not respond to psychotropic drugs, a condition called schizophrenia-treatment resistance. Fortunately, clozapine is a promising option for patients who exhibit treatment resistance. Unlike chlorpromazine, scientists have found that clozapine has fewer neurological side effects. Additionally, olanzapine and aripiprazole are well-known for their moderating effects on psychosis and are widely used in clinical practice. To further maximize drug efficacy, it is critical to deeply understand the receptors or signaling pathways central to the nervous system, such as serotonin, histamine, trace amines, dopamine, and G-protein coupled receptors. This article provides an overview of the receptors mentioned above, as well as the antipsychotics that interact with them, such as olanzapine, aripiprazole, clozapine, and chlorpromazine. Additionally, this article discusses the general pharmacology of these medications.
format Online
Article
Text
id pubmed-10142280
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-101422802023-04-29 Receptors Involved in Mental Disorders and the Use of Clozapine, Chlorpromazine, Olanzapine, and Aripiprazole to Treat Mental Disorders Mlambo, Ronald Liu, Jia Wang, Qian Tan, Songwen Chen, Chuanpin Pharmaceuticals (Basel) Review Mental illnesses are a global health challenge, and effective medicines are needed to treat these conditions. Psychotropic drugs are commonly prescribed to manage mental disorders, such as schizophrenia, but unfortunately, they can cause significant and undesirable side effects, such as myocarditis, erectile dysfunction, and obesity. Furthermore, some schizophrenic patients may not respond to psychotropic drugs, a condition called schizophrenia-treatment resistance. Fortunately, clozapine is a promising option for patients who exhibit treatment resistance. Unlike chlorpromazine, scientists have found that clozapine has fewer neurological side effects. Additionally, olanzapine and aripiprazole are well-known for their moderating effects on psychosis and are widely used in clinical practice. To further maximize drug efficacy, it is critical to deeply understand the receptors or signaling pathways central to the nervous system, such as serotonin, histamine, trace amines, dopamine, and G-protein coupled receptors. This article provides an overview of the receptors mentioned above, as well as the antipsychotics that interact with them, such as olanzapine, aripiprazole, clozapine, and chlorpromazine. Additionally, this article discusses the general pharmacology of these medications. MDPI 2023-04-17 /pmc/articles/PMC10142280/ /pubmed/37111360 http://dx.doi.org/10.3390/ph16040603 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Mlambo, Ronald
Liu, Jia
Wang, Qian
Tan, Songwen
Chen, Chuanpin
Receptors Involved in Mental Disorders and the Use of Clozapine, Chlorpromazine, Olanzapine, and Aripiprazole to Treat Mental Disorders
title Receptors Involved in Mental Disorders and the Use of Clozapine, Chlorpromazine, Olanzapine, and Aripiprazole to Treat Mental Disorders
title_full Receptors Involved in Mental Disorders and the Use of Clozapine, Chlorpromazine, Olanzapine, and Aripiprazole to Treat Mental Disorders
title_fullStr Receptors Involved in Mental Disorders and the Use of Clozapine, Chlorpromazine, Olanzapine, and Aripiprazole to Treat Mental Disorders
title_full_unstemmed Receptors Involved in Mental Disorders and the Use of Clozapine, Chlorpromazine, Olanzapine, and Aripiprazole to Treat Mental Disorders
title_short Receptors Involved in Mental Disorders and the Use of Clozapine, Chlorpromazine, Olanzapine, and Aripiprazole to Treat Mental Disorders
title_sort receptors involved in mental disorders and the use of clozapine, chlorpromazine, olanzapine, and aripiprazole to treat mental disorders
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10142280/
https://www.ncbi.nlm.nih.gov/pubmed/37111360
http://dx.doi.org/10.3390/ph16040603
work_keys_str_mv AT mlamboronald receptorsinvolvedinmentaldisordersandtheuseofclozapinechlorpromazineolanzapineandaripiprazoletotreatmentaldisorders
AT liujia receptorsinvolvedinmentaldisordersandtheuseofclozapinechlorpromazineolanzapineandaripiprazoletotreatmentaldisorders
AT wangqian receptorsinvolvedinmentaldisordersandtheuseofclozapinechlorpromazineolanzapineandaripiprazoletotreatmentaldisorders
AT tansongwen receptorsinvolvedinmentaldisordersandtheuseofclozapinechlorpromazineolanzapineandaripiprazoletotreatmentaldisorders
AT chenchuanpin receptorsinvolvedinmentaldisordersandtheuseofclozapinechlorpromazineolanzapineandaripiprazoletotreatmentaldisorders